Outlook Therapeutics Gains Following FDA Approval of Macular-Degeneration Drug — Update
By Josh Beckerman
Shares of Outlook Therapeutics posted wide swings as the Food and Drug Administration approved the company's Lytenava for treatment of neovascular age-related macular degeneration.
The stock closed up 6% to $1.41 and were recently at $1.40 after hours. Shares hit a intraday high of $1.75 prior to a trading halt and pared some of the earlier gains once trading resumed.
Outlook said it expects the drug to be available to eligible patients in the U.S. before year end. The company anticipates 12 years of market exclusivity under the Biologics Price Competition and Innovation Act.
On Dec. 31, shares closed at $1.58, then fell sharply as the FDA issued a complete response letter for Lytenava. In June, the FDA accepted a resubmitted biologics license application and set a Prescription Drug User Fee Act target action date of July 29.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
July 24, 2026 17:17 ET (21:17 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Why This Vanguard ETF Is One of the Best
The Best AI Stocks to Buy Now
United States